News & Opinion - 2022
– Medpage TodayHIPAA Protections End Where the Money Begins
CERC’s Robert Kaplan: “I'm alarmed my personal health info is being used for targeted marketing.”
– Milken Institute ReviewFixing Generic Drugs with Voluntary Privatized Regulation
In this article in the Milken Review, Kevin Schulman comments on the lack of oversight in the generic drug industry and proposes solutions to the crisis.
– NEJM CatalystWhat AI in Health Care Can Learn from the Long Road to Autonomous Vehicles
CERC’s Nirav Shah and his industry co-author use the concept of AI-assisted driving to help clinicians conceptualize a evolutionary trajectory to AI-assisted higher-value health care.
– CIVICA Insulin AnnouncementCivica’s Plan for Affordable Insulin Proves we can Bring Transparency to the Drug Market
CERC’s Kevin Schulman, an advisor to Civica, said it would transform the business model of the outpatient pharmacy market.
– Stanford GSBA Plan to Inject More Funding into the War on Antibiotic Resistance
CERC’s Kevin Schulman and Stanford Medicine's Neil Gandhi propose federal subsidies to accelerate R&D on urgently needed antibiotics.
– Health Services ResearchRacial disparities in healthcare and health
Kevin Schulman of CERC, and Stanford colleague Mayuri Chandran: Structural racism and the sociologic model of health provide new opportunities to better understand the impact of social determinants of health on outcomes.
– JAMA NetworkThe Dysfunctional Health Benefits Market and Implications for US Employers and Employees
In this Viewpoint by CERC’s David Scheinker, the solution to dysfunction in the health lies at the market level.